Tetra Bio-Pharma has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.
Tetra Bio-Pharma Inc?("Tetra" or "TBP"),?(TSX VENTURE: TBP) (OTCQB: TBPMF), has closed a private placement of units (the "Private Placement")?with its strategic partner Aphria Inc. ("Aphria") (TSX: APHA) (NYSE: APHA).